Now trading at their lowest level in three months, Moderna shares have struggled as experts question the long-term viability of the firm’s Covid-19 vaccine sales.
Moderna Crash Wipes Out Another $24 Billion After Supply Chain Issues Dent Covid Vaccine Sales
